On May 12, 2025, Guggenheim analyst Michael Schmidt reiterated a "Neutral" rating for SpringWorks Therapeutics (SWTX, Financial). The rating remains unchanged from the previous assessment.
In addition to maintaining the rating, the firm also held steady its price target for SWTX at $47.00 USD. This price target reflects no change from the prior assessment, maintaining its consistency in the valuation outlook for the company.
The analyst's decision to retain both the rating and the price target suggests a steady view on SpringWorks Therapeutics' market position and potential, with no anticipated major shifts in the company's trajectory according to Guggenheim's latest analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for SpringWorks Therapeutics Inc (SWTX, Financial) is $54.86 with a high estimate of $84.00 and a low estimate of $47.00. The average target implies an upside of 18.84% from the current price of $46.16. More detailed estimate data can be found on the SpringWorks Therapeutics Inc (SWTX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, SpringWorks Therapeutics Inc's (SWTX, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
